Royal Bank Of Canada Has Lowered Expectations for BeOne Medicines (NASDAQ:ONC) Stock Price

Posted by George Bondi on Aug 8th, 2026

BeOne Medicines (NASDAQ:ONC – Get Free Report) had its price target lowered by research analysts at Royal Bank Of Canada from $451.00 to $450.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Royal Bank Of Canada’s target price would indicate a potential upside of 29.21% from the company’s current price.

Several other equities research analysts have also recently commented on ONC. JPMorgan Chase & Co. lifted their target price on BeOne Medicines from $415.00 to $425.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Nomura raised BeOne Medicines to a “strong-buy” rating in a research note on Monday, July 27th. Zacks Research cut BeOne Medicines from a “strong-buy” rating to a “hold” rating in a report on Friday, July 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of BeOne Medicines in a research report on Friday, July 17th. Finally, Wells Fargo & Company assumed coverage on BeOne Medicines in a report on Monday, May 4th. They set an “overweight” rating and a $400.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $400.00.

Check Out Our Latest Research Report on BeOne Medicines

BeOne Medicines Price Performance

ONC opened at $348.27 on Thursday. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.40 and a quick ratio of 3.27. The stock has a market capitalization of $38.21 billion, a P/E ratio of 61.32 and a beta of 0.49. The company’s 50 day simple moving average is $296.52 and its 200-day simple moving average is $308.89. BeOne Medicines has a one year low of $253.95 and a one year high of $385.22.

BeOne Medicines (NASDAQ:ONC – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $2.05 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.65. BeOne Medicines had a net margin of 10.70% and a return on equity of 14.23%. The firm had revenue of $1.71 billion during the quarter, compared to analysts’ expectations of $1.66 billion. Sell-side analysts anticipate that BeOne Medicines will post 6.26 earnings per share for the current fiscal year.

Insider Buying and Selling at BeOne Medicines

In other news, SVP Chan Henry Lee sold 1,044 shares of the stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $323.69, for a total value of $337,932.36. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO John Oyler sold 61,397 shares of the firm’s stock in a transaction on Tuesday, July 21st. The stock was sold at an average price of $317.67, for a total value of $19,503,984.99. Following the completion of the transaction, the chief executive officer owned 9,180 shares in the company, valued at $2,916,210.60. This represents a 86.99% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 345,561 shares of company stock worth $105,625,947 over the last quarter. 6.19% of the stock is currently owned by insiders.

Institutional Investors Weigh In On BeOne Medicines

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of America Corp DE bought a new stake in shares of BeOne Medicines in the 2nd quarter valued at about $67,657,000. Man Group plc acquired a new stake in shares of BeOne Medicines in the 2nd quarter valued at approximately $59,031,000. BNP Paribas Financial Markets bought a new position in BeOne Medicines during the 2nd quarter worth approximately $38,337,000. First Trust Advisors LP grew its holdings in BeOne Medicines by 91.9% during the first quarter. First Trust Advisors LP now owns 241,426 shares of the company’s stock valued at $71,696,000 after purchasing an additional 115,601 shares during the period. Finally, Qube Research & Technologies Ltd acquired a new position in BeOne Medicines during the second quarter valued at approximately $26,034,000. Institutional investors own 48.55% of the company’s stock.

Key BeOne Medicines News

Here are the key news stories impacting BeOne Medicines this week:

Positive Sentiment: Strong Q2 performance: BeOne reported adjusted earnings of $2.05 per share, topping the $1.40 consensus estimate, while revenue reached $1.71 billion versus expectations of $1.66 billion. The earnings beat reinforces confidence in the company’s oncology portfolio and profitability. BeOne Medicines Q2 earnings report
Positive Sentiment: 2026 outlook raised: Management increased its full-year revenue forecast to approximately $6.6 billion-$6.8 billion, above Wall Street’s prior estimate of $6.5 billion, citing a 30% quarterly revenue surge. BeOne Medicines raises 2026 outlook
Positive Sentiment: Analyst targets moved higher: TD Cowen raised its target to $454 and assigned a Buy rating; Guggenheim increased its target to $430, Truist lifted its target to $418, and Citizens JMP raised its target to $405. RBC made a modest reduction to $450 but retained an Outperform rating. Collectively, the updates indicate substantial implied upside from recent trading levels. Analyst price-target updates
Positive Sentiment: Institutional buying: Bank of America, Man Group, BNP Paribas and other institutions recently established or expanded positions, suggesting continued professional-investor interest in ONC.
Neutral Sentiment: Insider sale was tax-related: CFO Aaron Rosenberg sold 1,157 shares valued at about $362,000 to cover tax withholding from vested equity awards. The transaction is therefore a limited bearish signal. SEC insider transaction filing
Negative Sentiment: Valuation risk: With a high earnings multiple and the stock trading below its 52-week high, investors may require continued rapid growth and execution to justify the current valuation.

BeOne Medicines Company Profile

(Get Free Report)

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.